Price: $45.45
· 1 day: +1.86% · 5 days: -11.58% · 1 month: -9.35% · YTD: +56.89%
As of 2026-11-06 21:00 UTC.
52-week range: $24.6 – $58.83 (currently at 61% of the range).
ARKG is in a turning up, momentum soft. $49.73 is the level overhead; $45 the first support below.
3 of 6 technical checks lean bearish.
| Trend | Turning up · below 50-day & 200-day |
|---|---|
| Momentum | RSI 46.28 · neutral · MACD bearish |
| Trend strength | ADX 18.9 · weak or range |
| Location | -8.6% vs 50-day MA |
| 52-week range | -20% from high · +83% from low |
| Volatility | ATR 2.94 · ~6.5%/day |
| Level | Type | Distance |
|---|---|---|
| $49.73 (resistance) | sma 50 | 9.42% |
| $50.0 (resistance) | round | 10.01% |
| $55.0 (resistance) | round | 21.01% |
| $45.0 (support) | round | -0.99% |
| $44.61 (support) | swing zone | -1.85% |
| $40.0 (support) | round | -11.99% |
| RSI (14) | 46.28 | MACD | -0.6044 |
|---|---|---|---|
| ADX (14) | 18.9 | ATR (14) | 2.94 |
| 50-day average | $49.73 | 200-day average | $37.73 |
Report of 2026-11-05.
ARK Genomic Revolution ETF (ARKG) fell 9.7% on November 5, 2026, to $44.85, extending a five-day slide of 18.6% that has pushed the fund 21% below its October 5 peak of $56.77. The drop is a sharp pullback inside a longer-term uptrend, and the evidence now leans positive for the next two to six weeks: the weekly trend is up, the pullback has reached oversold, and history after similar one-day drops favors the trend side. The balance of evidence has shifted from neutral to bullish, though conviction is medium, not high.
The immediate trigger for the selloff is a cluster of earnings reports from key holdings. SOPHiA GENETICS reported third-quarter revenue of $24.3 million, up 25% year-over-year, with an adjusted EBITDA loss that improved 31% to $6.1 million, and raised its full-year guidance — a solid print that did not stop the stock from falling with the rest of the basket. PTC Therapeutics reported total revenue of $358 million, including $276 million in product revenue, up from $201.7 million a year earlier, and raised its full-year guidance to $1.29–1.3 billion. Neither report explains a 9.7% one-day drop in the fund; the move is broader than any single holding.
The market itself is part of the story. SPY fell 3.4% on the day and 3.6% over five days, so ARKG's 18.6% five-day decline is far worse than the market's. The fund has lagged SPY by 7.0 percentage points over the last 50 days, even as it remains 18.1% ahead of SPY over the last 200 days. That divergence — strong long-term relative performance, weak recent relative performance — is the signature of a pullback inside an uptrend, not a broken thesis.
The debate about ARKG is not about the earnings of any single company. It is about whether the genomics theme is still in its growth phase or has peaked. The bull case rests on the sector's momentum: the iShares Biotechnology ETF (IBB) has risen 24% year-to-date through October 23, following a 28% gain in 2025, with two dozen of its 233 holdings more than doubling this year, according to CNBC. The bear case is that the theme is crowded and vulnerable to profit-taking after a 54.8% year-to-date gain in ARKG itself. The Forbes piece on Anthropic's DNA discovery, which coincided with declines in gene-editing stocks, shows how sensitive the basket is to headlines that question the pace of scientific progress.
The news flow this week is mixed but not negative. Ultima Genomics and Illumina both won contracts for Singapore's National Precision Medicine Phase III program, which aims to sequence approximately 450,000 individuals — a validation of the sequencing infrastructure that ARKG holds. The genotyping assay market is projected to grow from $24.29 billion in 2026 to $44.60 billion by 2031, a 12.9% CAGR, per MarketsandMarkets. None of this explains the 9.7% one-day drop; the move looks like a broad risk-off in high-beta growth, amplified by the fund's concentration in small-cap genomics names.
The long-term thesis is intact. ARKG trades above its 40-week average, and the 200-day average at $37.67 is well below the current price. The fund is in a pullback phase within a weekly uptrend — not a reversal. The 50-day average at $49.83 is above the 200-day average, and the price is 21% below its 52-week high of $56.77 but 80.7% above its 52-week low of $24.82. The trend is up, and the pullback has not broken it.
For the next two to six weeks, the balance of evidence leans positive. The pullback has reached oversold — the 14-day RSI is 46.36, which is not deeply oversold but is low for a fund that has been in a strong uptrend. History is on the trend side: after one-day drops of more than 5%, ARKG was higher a month later 70.9% of the time, with a median one-month move of +5.38% across 151 cases. The fund's 5-day decline of 18.6% is more than five times SPY's 3.6% drop, which is the kind of overshoot that tends to mean-revert. Conviction is medium, not high, because the fund is still below its 50-day average and has not yet shown a daily close above $45.00 on volume above its 20-day average — the breakout level that would confirm buyers are back.
The strongest case against a positive reading is that the selloff is not over. The fund is down 21% from its peak, and the 5-day drop of 18.6% is accelerating — the 1-day drop of 9.7% is the largest of the move. Volume is 13.5% below its 20-day average, which suggests the selling is not climactic but steady. If the market continues to fall — SPY is down 4.8% over the last month — ARKG could follow, and a weekly close below the 200-day average at $37.67 would change the picture entirely. That is why conviction is medium, not high: the evidence leans positive, but the market backdrop is not supportive.
The structure holds above $44.61, a swing zone that has acted as support. The fund closed at $44.85 on November 5, just above that level. A daily close below $44.61 would be the first crack in the structure, and a weekly close below the 200-day average at $37.67 would end the weekly uptrend. The 200-day average is the line that separates a pullback from a reversal.
The breakout level is a daily close above $45.00 on volume above its 20-day average. From $44.85, the first target is the 50-day average at $49.83, which gives a reward-to-risk of 4.3 to 1 against a stop at $43.88 — the swing zone minus a quarter of the 14-day ATR of $2.91. The second target is the 52-week high at $56.77, which gives a reward-to-risk of 10.5 to 1. Both meet the 3-to-1 threshold that makes a breakout worth the risk. The map is clear: a close above $45.00 opens the path to $49.83 and then $56.77, with a stop below $43.88.
The picture changes on a weekly close below $37.67, the 200-day average. That would break the long-term uptrend and shift the reading from bullish to bearish. The non-price fact that would change the picture is a fundamental deterioration in the genomics theme — for example, a major clinical trial failure or a regulatory setback for a key holding that calls the basket's growth story into question. No such event is on the horizon, but the sector is sensitive to headlines, as the Forbes piece on Anthropic's DNA discovery showed.
Interactive ARKG chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs